Business Wire

Bicara Therapeutics Presents Updated Interim Data from Ongoing Phase 1/1b Study of BCA101 in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC ...

BOSTON--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the presentation ...
Medical News Today

Adenocarcinoma of the cervix: What to know

Adenocarcinoma of the cervix is a less common type of cervical cancer. It can cause symptoms such as vaginal bleeding. Treatment can include radiation therapy and surgery. Adenocarcinoma of the cervix ...
MedPage Today

HPV Detectability: What are the Implications in Patients with Cervical Cancer?

Even though HPV positivity is a known factor in the diagnosis of cervical cancer, approximately 1 in 10 patients with cervical cancer test negative for HPV. A new study hypothesized a possible ...
Nasdaq

Bicara Therapeutics Reports Promising Phase 1/1b Trial Results for Ficerafusp Alfa in HPV-Negative Head and Neck Cancer

Bicara Therapeutics Inc. has announced promising data from its Phase 1/1b clinical trial of ficerafusp alfa, a novel bifunctional antibody, in combination with pembrolizumab for treating first-line ...
Business Wire

Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

BOSTON--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing transformative bifunctional therapies for patients with solid tumors, today announced the presentation ...